Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Myriad Genetics (MYGN) Short-Term Debt issuances (2017 - 2025)

Myriad Genetics has reported Short-Term Debt issuances over the past 5 years, most recently at $40.0 million for Q1 2025.

Quarterly Short-Term Debt issuances fell 33.33% to $40.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $40.0 million through Dec 2025, down 66.67% year-over-year, with the annual reading at $40.0 million for FY2025, 66.67% down from the prior year.
Short-Term Debt issuances was $40.0 million for Q1 2025 at Myriad Genetics, up from $20.0 million in the prior quarter.
Over five years, Short-Term Debt issuances peaked at $60.0 million in Q1 2024 and troughed at $20.0 million in Q2 2024.
The 3-year median for Short-Term Debt issuances is $40.0 million (2023), against an average of $34.3 million.
Year-over-year, Short-Term Debt issuances crashed 50.0% in 2024 and then crashed 33.33% in 2025.
A 3-year view of Short-Term Debt issuances shows it stood at $40.0 million in 2023, then crashed by 50.0% to $20.0 million in 2024, then skyrocketed by 100.0% to $40.0 million in 2025.
Per Business Quant, the three most recent readings for MYGN's Short-Term Debt issuances are $40.0 million (Q1 2025), $20.0 million (Q4 2024), and $20.0 million (Q3 2024).